(S)-C33 [C33(S)] is a potent and selective phosphodiesterase-9A (PDE9A) inhibitor that upregulates cGMP signaling. (S)-C33 protects against cardiac hypertrophy and postpones the transition to heart failure in rat models.
potent and selective phosphodiesterase-9A (PDE9A) inhibitor
Phosphodiesterase-9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of central nervous system diseases and diabetes. Here, we report the discovery of a new category of PDE9 inhibitors by rational design on the basis of the crystal structures.
Phosphodiesterase-9A (PDE9A) expression is upregulated during cardiac hypertrophy and heart failure. Accumulating evidence suggests that PDE9A might be a promising therapeutic target for heart diseases. The present study sought to investigate the effects and underlying mechanisms of C33(S), a novel
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.